Payment overview · 2025
General Payments
$665.69
31 reported records · 14 companies
Healthcare provider profile · identity verified
Gary Wang, MD
Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation · BUFFALO, NY · NPI 1053382051
Verified facts
What the public records show
CMS Open Payments records show Gary Wang, MD received $665.69 in general payments during 2025 across 31 reported records.
Lilly USA, LLC accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.67 | 17.4% | 5 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $98.93 | 14.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.00 | 13.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.44 | 9.5% | 4 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $58.32 | 8.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.84 | 6.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.46 | 5.6% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $33.65 | 5.0% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $27.90 | 4.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.31 | 4.0% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.72 | 3.3% | 1 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $19.42 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.04 | 2.7% | 1 | 2025 |
| Cepheid | Unresolved — no canonical attribution shown | $14.99 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $665.69 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $98.93 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $74.31 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.16 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $63.44 | 4 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $58.32 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.84 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $33.65 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Escitalopram Oxalate | Escitalopram Oxalate | 329 | 100 |
| Bupropion Xl | Bupropion Hcl | 305 | 75 |
| Lamotrigine | Lamotrigine | 245 | 66 |
| Oxcarbazepine | Oxcarbazepine | 243 | 70 |
| Clonidine Hcl | Clonidine Hcl | 211 | 66 |
| Metformin Hcl | Metformin Hcl | 182 | 44 |
| Gabapentin | Gabapentin | 139 | 31 |
| Methadone Hcl | Methadone Hcl | 117 | 30 |
| Topiramate | Topiramate | 112 | 23 |
| Naltrexone Hcl | Naltrexone Hcl | 103 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 18 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 86 | 11 |
| Clonidine | Clonidine | 77 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 70 | 14 |
| Mirtazapine | Mirtazapine | 61 | 11 |
| Ozempic | Semaglutide | 55 | suppressed |
| Baclofen | Baclofen | 52 | 12 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 11 |
| Meloxicam | Meloxicam | 38 | 11 |
| Celecoxib | Celecoxib | 35 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $665.69 · 31 records | Lilly USA, LLC | ABRYSVO, ACCRUFER, AFREZZA, COMIRNATY, Dysport, FREESTYLE LIBRE 3, Fabhalta, JARDIANCE, MOUNJARO, Ozempic, PREVNAR 20, RUCONEST, SPRINT PNS System, TWIIST, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error